Lymphoedema Evidence Library
Lymphoedema Evidence Library › Topics › Breast cancer-related lymphoedema

Breast cancer-related lymphoedema

Breast cancer-related lymphoedema (BCRL)

107 sources
All 107 sourcesReferences (RIS)Spreadsheet (CSV)

Evidence in one minute

  • Risk: higher with axillary dissection than sentinel biopsy, with radiotherapy and taxanes, BMI >25–30, and inactivity (ISL 2023). In 5 064 Turkish modified radical mastectomies, 19.9% developed lymphoedema (mean onset 29 months); BMI 30–34.9 OR 6.6. Low certainty (retrospective). Ay 2014
  • Prevention: exercise may reduce risk (ISL cites a meta-analysis, especially ≥5 nodes removed; the 2026 update finds the breast-cancer and ≥5-node estimates non-significant — revised 2026-10-09); post-operative physiotherapy associated with 10.4% vs 25.6% lymphoedema but confounded by adherence. Reverse lymphatic mapping and LYMPHA reduce incidence in several studies. Executive Committee of the International Society of Lymphology 2023
  • Surveillance: baseline and serial bilateral measurement; TDC forearm ratio ≥1.2 proposed for pre-clinical BCRL (research threshold). Mayrovitz 2014
  • Treatment: CDT; compression garments alone have the strongest trial support in early BCRL; MLD adds little to compression for volume. Executive Committee of the International Society of Lymphology 2023
  • Pneumatic compression at home: an advanced trunk-and-arm device beat a simple 4-chamber pump (−118 v +6 ml excess volume, 36 completers, attrition unreported, p=0.05) — very low certainty (revised 2026-10-08), check funding. Fife 2012
  • Taping: no effect on lymphoedema severity (SMD 0.04, 12 RCTs; low certainty); function, QoL and comfort gains very low certainty (AMSTAR 2 critically low; revised 2026-10-08). Yang 2024
  • HBOT does not reduce chronic arm lymphoedema (randomised phase II, academic funding). Low certainty (revised 2026-10-08). Gothard 2010
  • Surgery: the multicentre N-LVA RCT's primary outcome (Lymph-ICF total) was null at 6 months; only physical function differed, below the trial's own clinically important threshold; no volume difference (revised 2026-10-08). Jonis 2024 · Lee 2025
  • South Africa: ~67 certified therapists (2014), <10% in the public sector; no national BCRL guideline; proposed referral pathway. Marco 2014

Update 2026-10-08 — downloaded evidence

  • Burden in LMICs: pooled arm lymphoedema prevalence 27%, incidence 21%; BMI >25 OR ~2. Torgbenu 2020
  • Axillary dissection vs sentinel biopsy: +13.7% lymphoedema, +24% pain (67 studies); PREVENT 3-year chronic BCRL ~4% after SNB vs ~26% after ALND; rural residence, BMI, supraclavicular RT and taxanes add risk. Che Bakri NA 2023 · Boyages 2023
  • Immediate lymphatic reconstruction at ALND: 9.5% vs 32% BCRL (preliminary single-centre RCT, unblinded volume outcome; low certainty, revised 2026-10-08; the abstract's QoL, bioimpedance and garment claims were not significant). Coriddi 2023
  • Prophylactic sleeves reduce first-year arm swelling after axillary dissection (moderate; Paramanandam 2022) but lasting prevention is unproven (low) (revised 2026-10-09; see batch 3 below). Earlier evidence: PLACE stopped at 53% of target, 30% v 41%, HR 0.69 (0.39–1.23) — inconclusive, a moderate benefit not excluded (low certainty); CALGB 70305 tested an exercise package with an activity-only sleeve, not prophylactic compression (low). PREVENT compared BIS- v tape-triggered sleeves (no untreated arm): less tape-defined chronic BCRL with BIS (low certainty, ImpediMed-designed). Ridner 2022 Bundred 2023 · Paskett 2021
  • Resistance exercise is safe (moderate certainty); the pooled L-Dex −1.1 is a before-after change within exercise groups, not a benefit over control (revised 2026-10-08). Weight loss reduces both arms but not the inter-arm difference (low). Hasenoehrl 2020 · Tsai 2020 · Campbell 2019
  • LVA RCT (N-LVA): primary outcome null at 6 months; garment discontinuation (43%) is self-reported and not a randomised contrast; at 2 years the QALY gain was not significant and the probability of cost-effectiveness from a health-service view was 8% at €20 000/QALY (revised 2026-10-08). Jonis 2024 · Kleeven 2026
  • Stewart–Treves: biopsy new purple papules or atypical "cellulitis" in long-standing lymphoedema. da Costa Vieira RA 2019

Gaps

N-LVA, ILR, PLACE, CALGB 70305 and PREVENT trials now held. Still to come: N-LVA 2-year results and the final ILR report.

Update 2026-10-09 — open-access batch 1 (2020–2026 trials and reviews)

  • Exercise for prevention (revised 2026-10-09): the 2026 meta-analysis (17 RCTs) gives RR 0.71 (0.53–0.96) overall, low certainty, but for breast cancer arm lymphoedema alone RR 0.81 (0.61–1.08) and for ≥5 nodes removed 0.50 (0.24–1.02) — neither significant. Exercise is safe; a preventive effect is possible, not established. Plinsinga 2026
  • Axillary reverse mapping (Gennaro 2022): 21% v 42% measured BCRL at 1 year — low certainty. Gennaro 2022
  • Weight loss (BE-WEL 2024 feasibility RCT): 2–4% weight loss did not shrink the arm more than arm exercise alone; effects within run-in noise — very low. Harvie 2024

Update 2026-10-09 — open-access batch 2

  • MLD (revised 2026-10-09): no added benefit over the rest of decongestive therapy — moderate (EFforT-BCRL, sham-controlled). De Vrieze T 2022
  • Prophylactic sleeves: a 2025 review again finds little or no difference in BCRL risk — low; it double-counts one trial. Shahid 2025
  • Night-time compression in maintenance: low certainty of benefit. Borman 2026 · Early BCRL: garment-first is not shown inferior to intensive DLT (very low). Jeffs 2024

Update 2026-10-09 — papers supplied by Dr Weir

  • Night-time compression (revised 2026-10-09): an independent Canadian RCT (LYNC, 120 women) found night compression added to a day sleeve reduced excess volume by 11–15 percentage points over 12 weeks; self-bandaging worked as well as a US$450 night garment — moderate (sustained benefit low). With LYMphoNIGHT, two trials now agree. McNeely 2022
  • Sleeve at diagnosis of mild BCRL: a class 1 sleeve cut 6-month progression from 57% to 16% (Swedish RCT, 70 women, unblinded measurement) — low; 43% without a sleeve did not progress. Blom 2022

Update 2026-10-09 — SA CME papers (Sabinet)

  • SAMJ CME 2014 on BCRL management and SA service gaps; CME 2008 on breast radiotherapy (lymphoedema listed as a late effect only). Marco 2014 · Wilson 2008

Update 2026-10-09 — figures checked in the original PDFs

  • Exercise prevention (Plinsinga 2026): the pooled benefit comes from small trials; the largest trials are null — supports the existing "possible, not established" position. Prophylactic sleeves (PLACE): the sleeve and control curves separate early and come together after about 30 months — any effect may be delay rather than prevention. Plinsinga 2026 · Bundred 2023

Update 2026-10-09 — open-access batch 3

  • Prophylactic sleeves after axillary dissection (revised 2026-10-09): the largest trial (Paramanandam 2022, 307 women, Mumbai) found a sleeve worn for the first year cut arm swelling (volume ≥10%: 14% v 25%; BIS HR 0.61) — moderate for first-year swelling, low for lasting lymphoedema (PLACE curves converged after 30 months; first author funded by the sleeve maker). Position: offer a sleeve for the first year after axillary dissection with radiotherapy, with surveillance. Paramanandam 2022
  • Intensive CDT v garments first: Dayes 2013 (103 women) — 4 weeks of daily MLD and bandaging added no clinically important benefit over garments alone (29% v 23% reduction, CI −7% to 21%) — low. Supports garment-first care. Dayes 2013
  • Small trials of exercise after mastectomy (Hu 2026) and resistance training v MLD (Kumar 2026) — very low; laser adds nothing measurable to decongestive therapy (Yoon 2026, low); no drug or herbal agent works (Lommer 2026). Hu 2026 · Kumar 2026 · Yoon 2026 · Lommer 2026

Update 2026-10-09 — open-access batch 4

  • Risk by axillary treatment: ALND, or SNB with extensive regional node radiotherapy, carries the highest trigger rates — focus surveillance there (low). Boyages 2021
  • Measure both arms before surgery if surveillance is planned (low). Chen 2025
  • QoL companions: LEAP (no QoL difference) and PREVENT compression (uncontrolled) added. Paskett 2021 · Ridner 2022

Update 2026-10-09 — open-access batch 5

  • Education programmes after surgery improve arm function but did not prevent lymphoedema at 18 weeks (Shi 2023, 6 events) — very low. Shi 2023
  • Strength testing after ALND is reliable between physiotherapists (background for resistance exercise). Korsholm-Rosfort 2020

Update 2026-10-09 — open-access batch 6

  • Risk factors (Koelmeyer 2022, PREVENT, 918 women): ALND, taxanes, regional nodal irradiation, BMI >30 and rural residence; not air travel, hypertension, diabetes, mastectomy or seroma — moderate. Koelmeyer 2022
  • Education: preoperative one-to-one teaching helps the shoulder, not swelling (Byun 2022). Byun 2022

Update 2026-10-09 — open-access batch 7

  • Exercise safety: a year of recreational football did not increase lymphoedema (Bloomquist 2021); exercise and acupuncture did not provoke it (Giron 2025) — low. Bloomquist 2021 · Giron 2025
  • Education format: an online course was no better than a pamphlet (Ridner 2020, 160 women) — moderate. Ridner 2020

Update 2026-10-09 — open-access batch 8 (reviews)

  • Age: a weak review links older age to severity (Guliyeva 2021); PREVENT found age did not predict BCRL. Guliyeva 2021

Update 2026-10-09 — open-access batch 9 (reviews)

  • Carpal tunnel: BCRL does not appear to cause it, and carpal tunnel release is safe (Forte 2022). Forte 2022

Update 2026-10-09 — open-access batch 10 (reviews)

  • Risk calculators (Lin 2022): 17 models, all high risk of bias; use core risk factors instead. Lin 2022

Update 2026-10-09 — open-access batch 11 (reviews)

  • Precautions (Hunley 2024 evidence map, 37 studies): blood draws, injections, blood pressure measurement, minor trauma, heat and air travel on the at-risk side were mostly not associated with BCRL onset — low. "Just in case" restrictions are not evidence-based; focus education on early signs and weight. Hunley 2024
  • Breast reconstruction does not increase BCRL risk (IRR 0.58), regardless of type or timing (Laustsen-Kiel 2025) — low. Laustsen-Kiel 2025

Update 2026-10-09 — open-access batch 12 (reviews; final)

  • Prevention by exercise (Chen 2026, 11 RCTs, 1450 women): progressive resistance exercise after surgery reduced BCRL (RR 0.68, 0.53–0.88; I² 0%) — moderate. A network of 27 trials ranks compression plus resistance training highest, with effects fading over time (Zhu 2026) — low. Lumping all "physical therapies" together shows no clear effect (Sun 2026). Chen 2026 · Zhu 2026 · Sun 2026
  • Practical prevention package after ALND: sleeve for the first year (Paramanandam), progressive strength training (Chen), weight control, and surveillance with a pre-operative baseline.

How the evidence points

HighMod.LowV. lowNone
Positive031390
Null or negative031550

Sources on this page with a comparison, by the result of their primary outcome and the GRADE certainty of their main finding (Mod. = Moderate, V. low = Very low, None = not graded). Context sources are not counted. How direction is decided.

All 107 sources

More filters
Loading 107 sources…